IgA Nephropathy Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical

DelveInsight's "IgA Nephropathy Treatment Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of IgAN, historical and forecasted epidemiology, as well as the IgAN market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Unlock key insights into the IgA Nephropathy Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ IgA Nephropathy Therapeutics Market Outlook- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the IgA Nephropathy Market Report
• In April 2025, Chinook Therapeutics Inc. announced a study is to evaluate the effect of BION-1301 versus placebo on proteinuria in adults with IgA nephropathy. Participants will have assessments of safety and efficacy for 2.5 years (up to 134 weeks). To facilitate study participation over this time period, other visits may be remote (away from study site) for participants who elect to self-administer the study drug.
• In April 2025, Novartis Pharmaceuticals conducted a phase 1/2 study of BION-1301, a first-in-class humanized IgG4 anti-a proliferation-inducing ligand (APRIL) monoclonal antibody. The study will be conducted in three parts. Part 1: double-blind, randomized, placebo-controlled, single ascending dose (SAD) in healthy volunteers (HVs). Part 2: double-blind, randomized, placebo-controlled multiple ascending dose (MAD) in HVs. Part 3: Open-label, multiple dose (MD) in participants with IgAN. Part 4: Retreatment period.
• In April 2025, Calliditas Therapeutics AB organized a clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice.
• DelveInsight estimates that there were approximately 415 thousand prevalent cases of IgAN across the 7MM in 2024. These diagnosed prevalent cases are projected to rise by 2034 at a CAGR of 0.6%.
• In 2024, the US accounted for around 133 thousand diagnosed prevalent cases of IgAN, expected to increase by 2034.
• Between EU4 and the UK, Germany had the highest number of diagnosed prevalent cases of IgAN in 2024, with approximately 30 thousand cases, while Spain had the lowest, with around 5 thousand cases.
• In 2024, Japan recorded the highest number of diagnosed prevalent cases of IgAN among the 7MM, nearly 175 thousand, which is expected to rise by 2034.
• In terms of gender-specific diagnosed prevalent cases of IgAN, France had approximately 16 thousand male and 8 thousand female cases in 2024, with these numbers expected to rise by 2034.
• Regarding age-specific diagnosed prevalent cases of IgAN, the UK reported nearly 2 thousand, 11 thousand, 11 thousand, and 3 thousand cases in the 65 age groups in 2024. These numbers are expected to grow by 2034.
• The leading IgA Nephropathy Companies such as Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others
• Promising IgA Nephropathy Therapies such as Sibeprenlimab, Atrasentan, LNP023, Research programme, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, HR19042, Sparsentan, HR19042, and others.

Stay ahead in the competitive landscape of the IgA Nephropathy Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ IgA Nephropathy Treatment Market Size- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

IgA Nephropathy Epidemiology Segmentation in the 7MM
• Total IgA Nephropathy Diagnosed Prevalent Cases
• IgA Nephropathy Gender-specific diagnosed prevalent cases
• IgA Nephropathy Age-specific diagnosed prevalent cases

Download the report to understand which factors are driving IgA Nephropathy epidemiology trends @ IgA Nephropathy Prevalence- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

IgA Nephropathy Marketed Drugs
• VANRAFIA (atrasentan): Novartis
Atrasentan, a selective oral Endothelin A Receptor (ETAR) antagonist, is being developed for IgAN and other rare kidney disorders. Acquired by Novartis through the Chinook Therapeutics acquisition, atrasentan aims to reduce proteinuria and slow kidney function decline, aligning with Novartis' precision nephrology focus. Additionally, Novartis received US FDA accelerated approval for VANRAFIA, based on its ability to reduce proteinuria in IgAN patients, though its effect on kidney function decline remains unproven. Continued approval depends on results from an ongoing Phase III trial, with final data expected in Q1 2026.

• FILSPARI (sparsentan): Travere Therapeutics
FILSPARI is the first and only oral, once-daily, non-immunosuppressive therapy approved in both the US and Europe for IgAN. It targets glomerular injury by blocking endothelin-1 and angiotensin II, offering a long-term solution to preserve kidney function. Available through the FILSPARI Risk Evaluation and Mitigation Strategies (REMS) program due to potential risks, it is marketed in Europe by CSL Vifor and in Japan by Renalys Pharma, with registration-enabling study results expected in the second half of 2025.

• TARPEYO/KINPEYGO (budesonide): Asahi Kasei (Calliditas Therapeutics)
Budesonide delayed-release capsules, marketed as TARPEYO in the US, are approved to reduce proteinuria in adults with primary IgAN at risk of rapid progression. Targeted for ileal release, the drug modulates immune responses involved in IgA pathogenesis, significantly reducing proteinuria and stabilizing kidney function. In Europe, it is sold as KINPEYGO through a partnership with STADA Arzneimittel, with orphan drug status and market exclusivity until 2032. In Japan, Viatris is developing it as NEFECON (VR-205), with Phase III results expected in 2026.

IgA Nephropathy Emerging Drugs
• Povetacicept (ALPN-303): Vertex Pharmaceuticals
Povetacicept (ALPN-303) is a dual antagonist of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), key cytokines involved in B cell, T cell, and innate immune cell function. Engineered with a transmembrane activator and CAML interactor (TACI) domain, it demonstrates enhanced potency and superior binding affinity in preclinical studies compared to existing BAFF/APRIL inhibitors. Clinical data in IgAN have shown best-in-class efficacy, supporting its potential as a disease-modifying therapy.

• Atacicept: Vera Therapeutics
Atacicept is an investigational recombinant fusion protein designed to inhibit BAFF and APRIL, two cytokines central to B-cell survival and autoantibody production. By targeting these immune pathways, atacicept addresses a key pathogenic mechanism in IgAN driven by abnormal B-cell activity. In May 2024, the US FDA granted atacicept Breakthrough Therapy Designation for IgAN, recognizing its potential to offer significant clinical benefit.

• Zigakibart (FUB523): Novartis
Zigakibart (FUB523; formerly BION-1301) is a subcutaneous monoclonal antibody targeting APRIL, currently in Phase III development for IgAN, with regulatory filing anticipated in 2027. The therapeutic approach is based on modulating APRIL-mediated immune activity, which contributes to disease pathogenesis. Zigakibart was previously evaluated in a Phase I/II study: Parts 1 and 2 confirmed safety in healthy volunteers, while Part 3 investigated efficacy in IgAN patients. In November 2022, interim data from Cohorts 1 and 2 presented at ASN Kidney Week supported the selection of a 600 mg biweekly subcutaneous dose for advancement into Phase III trials.

To learn more about IgA Nephropathy Treatment guidelines, visit @ IgA Nephropathy Market Drivers and Barriers- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

IgA Nephropathy Companies
Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others.

IgA Nephropathy Drugs Market Insights
Two drug classes primarily define the treatment landscape for IgAN: endothelin receptor antagonists (ERA) and immunosuppressive agents. ERAs like VANRAFIA (atrasentan) and FILSPARI (sparsentan) have emerged as key options for managing proteinuria, a critical marker of IgAN progression. VANRAFIA targets the endothelin-1 pathway, which contributes to inflammation and fibrosis, while FILSPARI offers a dual-target approach by combining endothelin receptor A antagonism with angiotensin II receptor blockade. These treatments offer a non-immunosuppressive alternative, addressing proteinuria with fewer safety concerns than traditional immunosuppressive therapies.

IgA Nephropathy Market Outlook
IgAN, the most common primary glomerulonephritis, can progress to renal failure, driven by glomerular deposition of galactose-deficient IgA1-autoantibody complexes and subsequent inflammatory damage. Management centers on optimized supportive care-blood pressure control, proteinuria reduction, and lifestyle interventions-while the role of immunosuppressive therapy remains selective and risk-based. Despite advances, no cure exists, and treatment remains individualized based on disease severity and progression risk. The evolving landscape increasingly integrates targeted therapies, reflecting a shift toward precision medicine. Continued unmet needs in efficacy, safety, and personalization are expected to fuel sustained market growth.

Explore the dynamics of the IgA Nephropathy Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ IgA Nephropathy Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the IgA Nephropathy Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• IgA Nephropathy Companies- Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others
• IgA Nephropathy Therapies- Sibeprenlimab, Atrasentan, LNP023, Research programme, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB, HR19042, Sparsentan, HR19042, and others.
• IgA Nephropathy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• IgA Nephropathy Unmet Needs, KOL's views, Analyst's views, IgA Nephropathy Market Access and Reimbursement

To know more about IgA Nephropathy Companies working in the treatment market, visit @ IgA Nephropathy Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/iga-nephropathy-igan-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. IgA Nephropathy Market Report Introduction
3. IgAN Market Overview at a Glance
4. IgA Nephropathy Executive Summary
5. IgA Nephropathy Key Events
6. IgA Nephropathy Market Disease Background and Overview
7. IgA Nephropathy Methodology
8. IgA Nephropathy Epidemiology and Patient Population
9. IgA Nephropathy Patient Journey
10. IgA Nephropathy Marketed Drugs
11. IgA Nephropathy Emerging Drugs
12. IgA Nephropathy- 7MM Market Analysis
13. IgA Nephropathy KOL Views
14. IgA Nephropathy Unmet Needs
15. IgA Nephropathy SWOT Analysis
16. IgA Nephropathy Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac Implantable Electronic Devices Market- https://www.delveinsight.com/report-store/implantable-cardiac-monitors-market
Sleep Tech Devices Market- https://www.delveinsight.com/report-store/sleep-tech-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
NK Cell Therapy Market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive Airway Pressure Device Market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Urea Cycle Disorders Market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
Testicular Neoplasm Market- https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
Healthcare Competitive Benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Antibody Drug Conjugate Market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Total Knee Arthroplasty Market - https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Bone Growth Stimulator Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Surgical Mask & Respirator Market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.